Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06822517 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
A Phase 1 study, sponsored by Ventus Therapeutics U.S..
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT06822517 is a Phase 1 study that was terminated before completion, run by Ventus Therapeutics U.S.. The registered enrollment target is 29 participants.
The verdict
NCT06822517, a Phase 1 study, was terminated before completion, sponsored by Ventus Therapeutics U.S..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose. Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Interventions
- DRUG Placebo
- DRUG VENT-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2025-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06822517
The ClinicalTrials.gov registry entry for NCT06822517 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ventus Therapeutics U.S., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06822517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06822517 about?
NCT06822517 is a clinical study titled "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease". This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screeni...
What is the current status of trial NCT06822517?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2025-03-05. Estimated completion is 2025-10-09.
What interventions are being tested in trial NCT06822517?
The interventions under investigation include: Placebo (DRUG), VENT-02 (DRUG).
Who is sponsoring clinical trial NCT06822517?
This trial is sponsored by Ventus Therapeutics U.S., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.